Navigation Links
Novel therapeutic agents provide hope for patients with hard-to-treat blood disorders
Date:12/9/2012

ne system to attack and destroy myeloma cells, but also prevents the growth of new blood vessels and inhibits myeloma cell growth by reducing the supply of oxygen and nutrients to the myeloma cells. To evaluate whether a combination regimen with pomalidomide plus low-dose dexamethasone therapy might offer relapsed multiple myeloma patients better progression-free and overall survival than high-dose dexamethasone alone, researchers conducted a study in a population of patients with refractory or relapsed and refractory disease.

The open-label, multicenter, Phase III trial evaluated the safety and efficacy of pomalidomide and low-dose dexamethasone (LoDEX) combination as compared to high-dose dexamethasone (HiDEX) alone. A total of 455 patients were enrolled and randomized to receive regimens of either pomalidomide with LoDEX (Arm A, 302 patients) or HiDEX (Arm B, 153 patients) in a 28-day cycle until disease progression or severe toxicity. The primary endpoint was progression-free survival (PFS), while secondary endpoints included measures of safety, overall survival, and quality of life.

After a median follow-up of 18 weeks, patients who received the pomalidomide and LoDEX combination experienced significantly longer PFS compared with those who received HiDEX alone (15.7 vs. 8 weeks), and overall survival was also longer in the combination treatment arm. After an independent review committee concluded that the combination regimen offered survival advantage, the study's Data Safety Monitoring Board recommended that patients from Arm B be switched to Arm A to receive the combination treatment.

The combination regimen was well tolerated among the study participants, although some expected toxicities were reported in both groups, including low neutrophil count (42% in Arm A vs. 15% in Arm B), low platelet count (21% vs. 24%), and fever (7% vs. 0%). At the time of analysis, 45 percent of patients in Arm A and 25 percent of patients in Arm
'/>"/>

Contact: Andrea Slesinski
aslesinski@hematology.org
614-352-5096
American Society of Hematology
Source:Eurekalert

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Researchers develop novel 3-D culture system for inflammatory breast cancer
2. ACNP: Novel NMDA receptor modulator significantly reduces depression scores within hours
3. Scripps Florida scientists uncover a novel cooperative effort to stop cancer spread
4. Novel mechanism through which normal stromal cells become cancer-promoting cells identified
5. Novel breast screening technology increases diagnostic accuracy
6. UNC, Vanderbilt discover a new live vaccine approach for SARS and novel coronaviruses
7. Moffitt Cancer Center researchers identify novel metabolic programs driving aggressive brain tumors
8. Novel treatment strategies for epilepsy
9. Taiho Pharmaceutical unveils data on 8 novel anticancer compounds
10. Researchers ID potential patient population who may benefit from novel anti-platelet treatment
11. Undertreatment of common heart condition persists despite rapid adoption of novel therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... 02, 2015 First Choice Emergency ... rooms in the United States, named Kenneth Alan Totz, ... Jones Road facility. , “We are pleased to ... Road facility,” said Dr. James M. Muzzarelli, Executive Medical ... Totz received his undergraduate degree from St. Edwards University ...
(Date:6/2/2015)... Amercanex, the American Cannabis Exchange, ... become Amercanex’s new Chief Technology Officer. Amercanex is ... cultivators, wholesale distributors and retail vendors can buy, ... transparent intra-state market. , Jim Miller is an ... space, helping innovative technology companies deliver on their ...
(Date:6/2/2015)... 02, 2015 FDA approved Orlistat for ... patients after a satisfactory doctor consultation. The less potent, over-the-counter ... several years and has the longest track record as an ... enzyme that breaks down fats in foods, Orlistat treatment prevents ... intestinal system to be excreted through feces. , ...
(Date:6/2/2015)... Vail, Colorado (PRWEB) June 02, 2015 ... and Chief Medical Officer at the Steadman Philippon Research ... It Too Early for Single Sport Specialization? ” This ... for Sports Medicine (AOSSM) Research Committee that was recently ... the data for this project was limited, there is ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 Colleen’s Dream ... has granted $70,000 to the UNMC to support ovarian cancer ... Billy Cundiff, a member of the Colleen’s Dream Foundation Board ... was the biggest to date for Colleen’s Dream Foundation and ... in Omaha. , “Dr. Wang is a rising star in ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room Announces Dr. Kenneth Alan Totz as New Medical Director of Houston – Jones Road Facility 2Health News:Amercanex Names Jim Miller to CTO Position 2Health News:Diet Doc Adds FDA Approved Orlistat to their Medically Supervised Diet Plans, Offering Their Patients another Option for Trimming Fat from the Hard to Reach Areas 2Health News:Diet Doc Adds FDA Approved Orlistat to their Medically Supervised Diet Plans, Offering Their Patients another Option for Trimming Fat from the Hard to Reach Areas 3Health News:Diet Doc Adds FDA Approved Orlistat to their Medically Supervised Diet Plans, Offering Their Patients another Option for Trimming Fat from the Hard to Reach Areas 4Health News:Early Single Sport Specialization May Put Youth Athletes at Risk for Overuse Injuries According to Colorado Knee Specialist Robert LaPrade, MD, PhD 2Health News:Early Single Sport Specialization May Put Youth Athletes at Risk for Overuse Injuries According to Colorado Knee Specialist Robert LaPrade, MD, PhD 3Health News:Colleen’s Dream Foundation Grants $70,000 to the University of Nebraska Medical Center (UNMC) to Support Ovarian Cancer Research 2Health News:Colleen’s Dream Foundation Grants $70,000 to the University of Nebraska Medical Center (UNMC) to Support Ovarian Cancer Research 3
... twins were conjoined from the breast bone to the ... pediatricians and nurses at Children,s Hospital of Pittsburgh of ... procedure.The 2-year-old twin girls -- Dagian and Danielle Lee, ... began at 6:30 a.m. Saturday, Dec. 13, 2008, and ...
... lead to more headaches, new study suggests , , MONDAY, Feb. ... by taking naps to sleep it off, but they run ... patterns and perpetuating the cycle of headaches, a new study ... things people tried to treat their headaches, and they rated ...
... a statement by American Heart Association President Timothy Gardner, ... provisions in the economic stimulus package are a win-win ... with increased financial burdens. Americans suffering from chronic ... -- see a doctor or pay for food and ...
... One of the nation,s first group of fertility ... cost reduction to patients challenged by economic downturnSAN ... a 25th-anniversary celebration, one of the nation,s first ... to couples and individuals struggling to find ways ...
... ARLINGTON, Texas, Feb. 16 Across the nation, countless ... executives at one North Texas healthcare company took some ... from being another victim to the economic crisis.2009 looks ... now in its 7th year. One year ago ten ...
... AlphaVax announced today that it has ... Regulatory, Quality and Clinical Operations. In this capacity ... the areas of regulatory and quality affairs and ... trials, developing regulatory strategy and gaining regulatory approval ...
Cached Medicine News:Health News:Conjoined Twins Separated by Surgical Team at Children's Hospital of Pittsburgh of UPMC During Complex, 24-Hour Procedure 2Health News:Using Sleep to Manage Headaches May Cause Insomnia 2Health News:Using Sleep to Manage Headaches May Cause Insomnia 3Health News:Statement by American Heart Association President Timothy Gardner, M.D. on Congressional Approval of Economic Stimulus Package 2Health News:Bay Area Fertility Clinic to Offer Special Help During Recession 2Health News:Staying Healthy in 2009 2Health News:AlphaVax Announces New Vice President of Regulatory, Quality and Clinical Operations 2
(Date:6/1/2015)... Novel t reatments   entering the ... GBI Research . ... driven primarily by the introduction of numerous premium therapies, particularly ... or combine with generic chemotherapies. Analysis from business ... Market to 2020 - forecasts the value of the ...
(Date:6/1/2015)... NEW YORK , June 1, 2015 ... FDA-approved transcutaneous electrical nerve stimulation device specifically authorized for ... released significant data from a new PET trial showing ... the areas in the brain in migraine patients, namely ... Positron Emission Tomography (PET) scan, which is an imaging test of ...
(Date:6/1/2015)... , May 29, 2015 Research ... addition of the "Global A Dialyzer Reprocessing ... report to their offering. The ... ) Industry Report 2014 is a professional and ... A dialyzer reprocessing machine industry. The report ...
Breaking Medicine Technology:New Therapies to Enhance Increasingly Competitive Non-Small Cell Lung Cancer Treatment Market 2New Therapies to Enhance Increasingly Competitive Non-Small Cell Lung Cancer Treatment Market 3New Study Shows CEFALY Returns Normal Metabolic Activity to Brain Areas in Migraine Patients 2Global A Dialyzer Reprocessing Machine (A Dialyzer Reprocessor) Industry Report 2014 - Development Trends Forecasts to 2020 2Global A Dialyzer Reprocessing Machine (A Dialyzer Reprocessor) Industry Report 2014 - Development Trends Forecasts to 2020 3
... Loss, Lower Blood Sugar and Improved A1CHORSHAM, Pa., April 21 ... loss program that delivers to your door, today announced the ... specifically for the approximately 24 million Americans with diabetes, as ... for diabetes. In a clinical study at Temple ...
... clinical trial strategies for personalized approach to cancer ... a wholly-owned subsidiary of Cell Therapeutics, Inc. (CTI) ... preclinical study, which utilized RNA interference (RNAi) and ... vulnerability" - that enhance the anti-tumor response to ...
Cached Medicine Technology:New Weight Loss Hope for People with Diabetes 2New Weight Loss Hope for People with Diabetes 3New Weight Loss Hope for People with Diabetes 4New Weight Loss Hope for People with Diabetes 5New Weight Loss Hope for People with Diabetes 6Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin 2Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin 3Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin 4
... developed in surgeon's desire to have the ... instrument with the strength to maneuver into ... bending or breaking. Arthrotek Hand Instruments are ... the surgeon's hand. This new generation of ...
... Arthrotek® Precision Hand Instruments were developed in ... feel, while still having an instrument with ... without the fear of the bending or ... and manufactured to conform to the surgeon's ...
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
... Instruments were developed in surgeon's desire to ... having an instrument with the strength to ... of the bending or breaking. Arthrotek Hand ... conform to the surgeon's hand. This new ...
Medicine Products: